Pheochromocytoma - Pipeline Insight, 2021
This report can be delivered to the clients within 24 Hours
DelveInsight’s, “Pheochromocytoma - Pipeline Insight, 2021,” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Pheochromocytoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Pheochromocytoma: Overview
Pheochromocytoma is a rare tumor that usually starts in the cells of one of your adrenal glands. It results in the release of too much epinephrine and norepinephrine, hormones that control heart rate, metabolism, and blood pressure. Pheochromocytoma may occur as a single tumor or as more than one growth. It usually develops in the center (medulla) of one or both adrenal glands. Symptoms associated with pheochromocytomas include high blood pressure (hypertension), headaches, excessive sweating, and/or heart palpitations. In approximately 25 to 35 percent of cases, pheochromocytomas may be inherited as an autosomal dominant trait. Blood and urine analysis can confirm a diagnosis of pheochromocytoma by detecting elevated levels of catecholamines or its metabolites in the urine and blood (plasma). Phenoxybenzamine or a similar drug is generally given to stop hormone action. The most common surgical procedure for treating pheochromocytoma is laparoscopic adrenalectomy. Radiation therapy, in which radiation is used to target and destroy cancer cells, and certain combinations of anticancer drugs (chemotherapy) may also be used to treat individuals with malignant pheochromocytoma.
'Pheochromocytoma - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pheochromocytoma pipeline landscape is provided which includes the disease overview and Pheochromocytoma treatment guidelines. The assessment part of the report embraces, in depth Pheochromocytoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pheochromocytoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Pheochromocytoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Pheochromocytoma Emerging Drugs
Further product details are provided in the report……..
Pheochromocytoma: Therapeutic Assessment
This segment of the report provides insights about the different Pheochromocytoma drugs segregated based on following parameters that define the scope of the report, such as:
Pheochromocytoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pheochromocytoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pheochromocytoma drugs.
Pheochromocytoma Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Pheochromocytoma - Pipeline Insight, 2021,” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Pheochromocytoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Pheochromocytoma: Overview
Pheochromocytoma is a rare tumor that usually starts in the cells of one of your adrenal glands. It results in the release of too much epinephrine and norepinephrine, hormones that control heart rate, metabolism, and blood pressure. Pheochromocytoma may occur as a single tumor or as more than one growth. It usually develops in the center (medulla) of one or both adrenal glands. Symptoms associated with pheochromocytomas include high blood pressure (hypertension), headaches, excessive sweating, and/or heart palpitations. In approximately 25 to 35 percent of cases, pheochromocytomas may be inherited as an autosomal dominant trait. Blood and urine analysis can confirm a diagnosis of pheochromocytoma by detecting elevated levels of catecholamines or its metabolites in the urine and blood (plasma). Phenoxybenzamine or a similar drug is generally given to stop hormone action. The most common surgical procedure for treating pheochromocytoma is laparoscopic adrenalectomy. Radiation therapy, in which radiation is used to target and destroy cancer cells, and certain combinations of anticancer drugs (chemotherapy) may also be used to treat individuals with malignant pheochromocytoma.
'Pheochromocytoma - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pheochromocytoma pipeline landscape is provided which includes the disease overview and Pheochromocytoma treatment guidelines. The assessment part of the report embraces, in depth Pheochromocytoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pheochromocytoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Pheochromocytoma R&D. The therapies under development are focused on novel approaches to treat/improve Pheochromocytoma.
This segment of the Pheochromocytoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Pheochromocytoma Emerging Drugs
- Sunitinib: Pfizer
- Guadecitabine: Astex Pharmaceuticals
Further product details are provided in the report……..
Pheochromocytoma: Therapeutic Assessment
This segment of the report provides insights about the different Pheochromocytoma drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Pheochromocytoma
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Pheochromocytoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pheochromocytoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pheochromocytoma drugs.
Pheochromocytoma Report Insights
- Pheochromocytoma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Pheochromocytoma drugs?
- How many Pheochromocytoma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pheochromocytoma?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Pheochromocytoma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Pheochromocytoma and their status?
- What are the key designations that have been granted to the emerging drugs?
- Pfizer
- Exelixis
- Ipsen
- Genentech
- Astex Pharmaceuticals
- Advanced Accelerator Applications
- Sunitinib
- Cabozantinib
- Atezolizumab
- Guadecitabine
- Lutetium-177 oxodotreotide
Introduction
Executive Summary
Pheochromocytoma: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Pheochromocytoma – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• Pheochromocytoma companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Pheochromocytoma Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Preregistration)
• Comparative Analysis
Drug name: Company name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
Sunitinib: Pfizer
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
• Comparative Analysis
Drug name: Company name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
• Comparative Analysis
Drug name: Company name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Pheochromocytoma Key Companies
Pheochromocytoma Key Products
Pheochromocytoma- Unmet Needs
Pheochromocytoma- Market Drivers and Barriers
Pheochromocytoma- Future Perspectives and Conclusion
Pheochromocytoma Analyst Views
Pheochromocytoma Key Companies
Appendix
Executive Summary
Pheochromocytoma: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Pheochromocytoma – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• Pheochromocytoma companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Pheochromocytoma Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Preregistration)
• Comparative Analysis
Drug name: Company name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
Sunitinib: Pfizer
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
• Comparative Analysis
Drug name: Company name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
• Comparative Analysis
Drug name: Company name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Pheochromocytoma Key Companies
Pheochromocytoma Key Products
Pheochromocytoma- Unmet Needs
Pheochromocytoma- Market Drivers and Barriers
Pheochromocytoma- Future Perspectives and Conclusion
Pheochromocytoma Analyst Views
Pheochromocytoma Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Pheochromocytoma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Pheochromocytoma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Pheochromocytoma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Pheochromocytoma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
